Invisible virus is being evaluated as the next generation of compassionate cancer cures
August 10, 2012
The investigative FOXNews journalists caught up with the clinicians, nurses and researchers at California Veterinary Specialists Angel Care Cancer Center to learn how an invisible virus is being evaluated as the next generation of compassionate cancer cures in dogs, cats and people. Angel Care Cancer Center, a separate but allied non-profit research organization, the Special Care Foundation for Companion Animals and the San Diego based company Genelux have teamed up to affirm the safety an efficacy of a new cancer killing virus. The therapy includes a modification of a virus that has been used worldwide to wipe out smallpox as a threat to human health. Families who bring their beloved pets with cancer to Angel Care seek the highest level of advanced yet gentle cancer care and novel, new therapies that are likely to become the therapies of the future. The purpose of the study is to determine the optimum way of treating these dogs with cancer while taking these results to develop new approaches to enhance the cure rates in children and adults.
The CVS Angel Care Cancer Center is a comprehensive cancer center that provides direct care for patients with cancer and their families. This team offers innovative clinical research to provide the very best diagnostics and treatments available to fight against cancer. They are a group of veterinarians, veterinary nurses, and human physicians that share a mutual philosophy: science may provide a cure, but compassionate care comes from the heart. The goal is to do everything possible to not only win the fight against cancer, but to ensure the treatment is healing, not hurting.
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer PatientsMay 31, 2012
SAN DIEGO, May 31,2012 -- Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best–in-class vaccinia virus based oncolytic viral therapies and companion diagnostics for human cancer patients, today announced the start of a ground-breaking clinical study involving the oncolytic Vaccinia virus V-VET1 in canine cancer patients with various measurable malignancies. Although oncolytic viruses are being more extensively evaluated in humans, this study is the first of its kind
We are in a process developing a new therapy for dogs with lymphoma that harnesses the immune system to destroy its own cancer. With appropriate therapy we are able to not only enhance and improve their quality of life but also extend that life and reduce the need for chemotherapy. This non-invasive, fully-funded study is one in which we take animals that have lymphoma and willing families who are excited about exploring new opportunities that will enhance and improve the quality of life of a pet with cancer. The veterinary health team...
In honor on National Veterinary Technician Week, CVS would like to thank each and every one of our dedicated technicians for their hard work, compassionate care and invaluable service to the veterinary field. Pictured are a few of our wonderful technicians from all three hospitals.
The word cancer is as dark and empty as the disease it defines. A diagnosis of cancer often brings with it feelings of overwhelming fear, a spiraling sense of loss of control, and most devastating of all, the loss of hope. This occurs regardless of whether the patient is a human family member or a precious pet. I know, because I am a veterinary oncologist at California Veterinary Specialists Angel Care Cancer Center and am given the honor of doing everything I can to defeat cancer in my animal patients with compassionate care. Like my fellow...
Dr. Ogilvie is directing a ground breaking canine clinical trial using a new and revolutionary non-invasive medical device called Voyager. "Voyager is just beginning its voyage as we are beginning the process of identifying the cancers its most effective to treat. It seems to have a broad spectrum of efficacy while being quite safe." The Voyager results are remarkable. Rapid and durable tumor response has been seen in many patients, resulting in partial and complete remissions. After one week of treatment, Voyager safely eliminated 90% of one..